e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
Stephen G. Noorduyn, Karissa Johnston, Kathy Osenenko, Niroshan Sriskandarajah, Alain Gendron, Lawrence Mbuagbaw
Source:
ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
Journal Issue:
October
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Stephen G. Noorduyn, Karissa Johnston, Kathy Osenenko, Niroshan Sriskandarajah, Alain Gendron, Lawrence Mbuagbaw. Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma. ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Impact of omalizumab in patients with severe asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Exacerbations of severe asthma in patients treated with mepolizumab
Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018
Year: 2018
Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Source: International Congress 2017 – Asthma management
Year: 2017
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
Source: Virtual Congress 2020 – How do different treatment strategies translate into costs
Year: 2020
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007
Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma.
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept